Cutaneous Melanoma
Information
- Disease name
- Cutaneous Melanoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03761017 | Active, not recruiting | Phase 1 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | December 12, 2018 | December 2024 |
| NCT01942603 | Active, not recruiting | Minimal SN Tumor Burden | July 2009 | December 2031 | |
| NCT02791334 | Active, not recruiting | Phase 1 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | June 29, 2016 | July 2024 |
| NCT02129075 | Completed | Phase 2 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | April 9, 2014 | May 18, 2018 |
| NCT04789421 | Completed | N/A | Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management | March 1, 2016 | March 16, 2020 |
| NCT04551352 | Completed | Phase 1 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | October 28, 2020 | July 28, 2022 |
| NCT02519322 | Completed | Phase 2 | Neoadjuvant and Adjuvant Checkpoint Blockade | February 2, 2016 | January 26, 2023 |
| NCT03633110 | Completed | Phase 1/Phase 2 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | August 29, 2018 | February 28, 2022 |
| NCT00679289 | Completed | Phase 2 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | March 28, 2008 | February 3, 2014 |
| NCT03843593 | Completed | A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery | February 14, 2019 | December 29, 2022 | |
| NCT03620019 | Completed | Phase 2 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | September 25, 2018 | August 15, 2023 |
| NCT03628417 | Completed | N/A | Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases | September 20, 2016 | June 4, 2019 |
| NCT02831634 | Completed | N/A | A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope) | June 9, 2016 | March 1, 2018 |
| NCT04274816 | Completed | Phase 1 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | July 10, 2012 | February 27, 2014 |
| NCT01444560 | Completed | miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi | December 2008 | September 2011 | |
| NCT05675709 | Enrolling by invitation | N/A | Enhancing Skin Cancer Early Detection and Treatment in Primary Care | April 25, 2023 | December 30, 2024 |
| NCT01728051 | No longer available | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | |||
| NCT06319196 | Recruiting | Phase 2 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | May 1, 2024 | February 15, 2030 |
| NCT03611868 | Recruiting | Phase 1/Phase 2 | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | August 29, 2018 | March 30, 2025 |
| NCT03699995 | Recruiting | N/A | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | May 18, 2018 | December 31, 2026 |
| NCT03767348 | Recruiting | Phase 2 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | September 20, 2017 | November 2024 |
| NCT03842943 | Recruiting | Phase 2 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | July 3, 2019 | June 1, 2028 |
| NCT03947385 | Recruiting | Phase 1/Phase 2 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | June 28, 2019 | May 31, 2025 |
| NCT04020809 | Recruiting | Phase 1 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | September 25, 2020 | December 2025 |
| NCT05520099 | Recruiting | Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | June 26, 2023 | January 2027 | |
| NCT05544929 | Recruiting | Phase 1 | A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | October 26, 2022 | February 20, 2026 |
| NCT05571839 | Recruiting | Phase 1 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | January 3, 2023 | September 30, 2028 |
| NCT05576077 | Recruiting | Phase 1 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | January 17, 2023 | June 30, 2025 |
| NCT05578872 | Recruiting | Phase 1/Phase 2 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | December 16, 2022 | December 2024 |
| NCT05628883 | Recruiting | Phase 1 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | November 22, 2022 | December 31, 2026 |
| NCT05669430 | Recruiting | Phase 1 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | March 23, 2023 | June 15, 2026 |
| NCT05970497 | Recruiting | Phase 1 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | October 31, 2023 | July 2026 |
| NCT06008977 | Recruiting | N/A | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | December 2023 | May 2025 |
| NCT06223659 | Recruiting | Phase 2 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | December 19, 2023 | December 31, 2025 |
| NCT04253080 | Recruiting | N/A | Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors | April 12, 2022 | February 2025 |
| NCT04702854 | Recruiting | N/A | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma | March 2024 | March 2025 |
| NCT04706962 | Recruiting | Phase 1 | TH1902 in Patients With Advanced Solid Tumors | March 4, 2021 | December 2024 |
| NCT04778449 | Recruiting | Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | August 26, 2015 | December 31, 2026 | |
| NCT04792463 | Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | March 3, 2015 | July 1, 2026 | |
| NCT04830124 | Recruiting | Phase 2 | Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 | May 27, 2021 | September 2025 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT05253872 | Recruiting | N/A | The MELAcare Study: A New Method for Surveillance of Melanoma Patients | March 9, 2022 | March 2028 |
| NCT05283330 | Recruiting | Phase 1 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | December 22, 2022 | January 2025 |
| NCT05358938 | Recruiting | Early Phase 1 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | June 21, 2022 | September 2024 |
| NCT04042480 | Terminated | Phase 1 | A Study of SGN-CD228A in Advanced Solid Tumors | September 3, 2019 | March 9, 2023 |
| NCT05219578 | Terminated | Phase 1/Phase 2 | RTX-224 Monotherapy in Patients With Solid Tumors | January 12, 2022 | November 30, 2022 |
| NCT04254107 | Terminated | Phase 1 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | May 29, 2020 | December 1, 2023 |
| NCT02968680 | Terminated | Phase 1 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | April 26, 2017 | January 9, 2020 |
| NCT02355587 | Terminated | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes | March 2014 | July 31, 2021 | |
| NCT02288897 | Terminated | Phase 3 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | April 2015 | September 2019 |
| NCT02355574 | Terminated | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results | June 2014 | July 2021 | |
| NCT01729663 | Unknown status | Phase 2/Phase 3 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | April 2009 | |
| NCT04625491 | Unknown status | Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. | January 1, 2000 | December 2021 | |
| NCT05482074 | Withdrawn | Phase 2 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | October 4, 2022 | May 1, 2027 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012056